Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (8553)	3/14/1998 10:41:00 PM
From: DMore	Read Replies (1) \| Respond to of 14328

Strep A running wild in Texas. I gathered from the tone on the conference call that the 50% eps growth is lowballed. I think they know they will come in higher but rather than possibly disappoint the market, a higher number will be very positive. With the currency change, higher sales and margins and less overhead, .09 would be disappointing. Management is not stupid and knows that when you miss estimates you get killed, yet upside surprises can really be a boost. The increase in liabs. was from acquisitions and financing on the new building. Goodwill was written off, thus the decrease in s/h equity. They mentioned getting to National Market system, all we need is $3.25 plus in price and all other requirements are met. I say all we need, we can't get $2.25 now. I still say either Centocor, Clark or an institution is selling. Noone else controls enough paper to do this kind if selling. It is highly unlikely all the shareholders decided to dump in this area. They would be selling for losses, except for the groups mentioned above. Tone of call was very positive. We still need of couple of major announcements on sales or major partners. Where is our major for H-pylori? When is Bayer going to start pulling their weight? Ronan also mentioned using irish firms to help get US institutional players. let's get started ASAP! D